JP2011526693A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526693A5
JP2011526693A5 JP2011516713A JP2011516713A JP2011526693A5 JP 2011526693 A5 JP2011526693 A5 JP 2011526693A5 JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011526693 A5 JP2011526693 A5 JP 2011526693A5
Authority
JP
Japan
Prior art keywords
determinants
tumor
subject
determinant
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011516713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/048862 external-priority patent/WO2009158620A2/en
Publication of JP2011526693A publication Critical patent/JP2011526693A/ja
Publication of JP2011526693A5 publication Critical patent/JP2011526693A5/ja
Withdrawn legal-status Critical Current

Links

JP2011516713A 2008-06-26 2009-06-26 転移に関連する徴候および決定因子、ならびにそれらの使用方法 Withdrawn JP2011526693A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
US61/075,933 2008-06-26
PCT/US2009/048862 WO2009158620A2 (en) 2008-06-26 2009-06-26 Signatures and determinants associated with metastasis methods of use thereof

Publications (2)

Publication Number Publication Date
JP2011526693A JP2011526693A (ja) 2011-10-13
JP2011526693A5 true JP2011526693A5 (enExample) 2012-05-31

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011516713A Withdrawn JP2011526693A (ja) 2008-06-26 2009-06-26 転移に関連する徴候および決定因子、ならびにそれらの使用方法

Country Status (14)

Country Link
US (1) US20110182881A1 (enExample)
EP (1) EP2307886A2 (enExample)
JP (1) JP2011526693A (enExample)
KR (1) KR20110036056A (enExample)
CN (1) CN102132160A (enExample)
AU (1) AU2009262022A1 (enExample)
BR (1) BRPI0914734A2 (enExample)
CA (1) CA2728674A1 (enExample)
IL (1) IL210245A0 (enExample)
MX (1) MX2010014280A (enExample)
NZ (1) NZ590385A (enExample)
RU (1) RU2011102743A (enExample)
WO (1) WO2009158620A2 (enExample)
ZA (1) ZA201100225B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
CA2790284C (en) 2010-02-17 2019-01-08 Takeda Pharmaceutical Company Limited Thieno-pyrimidine compounds having cdc7 inhibitory activity
JP2013533960A (ja) 2010-06-01 2013-08-29 トドス メディカル リミテッド がんの診断
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8880457B2 (en) * 2010-11-05 2014-11-04 Allegheny-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
EP2707710B1 (en) 2011-05-11 2022-08-17 Todos Medical Ltd. Diagnosis of cancer based on infrared spectroscopic analysis of dried blood plasma samples
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
JP6133297B2 (ja) * 2011-09-06 2017-05-24 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物
US10322194B2 (en) 2012-08-31 2019-06-18 Sloan-Kettering Institute For Cancer Research Particles, methods and uses thereof
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP6465811B2 (ja) 2012-12-19 2019-02-06 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 多様式の粒子、方法およびその使用
US20160000329A1 (en) 2013-02-20 2016-01-07 Sloan-Kettering Institute For Cancer Research Wide field raman imaging apparatus and associated methods
NZ712575A (en) * 2013-03-14 2019-08-30 Castle Biosciences Inc Methods for predicting risk of metastasis in cutaneous melanoma
US9804145B2 (en) 2013-05-28 2017-10-31 Todos Medical Ltd. Infrared analysis of benign tumors
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
US20150252434A1 (en) * 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10688202B2 (en) 2014-07-28 2020-06-23 Memorial Sloan-Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
EP3259578B1 (en) * 2015-02-17 2019-10-23 Siemens Healthcare Diagnostics Inc. Model-based methods and testing apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
US10919089B2 (en) 2015-07-01 2021-02-16 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
CN109844140A (zh) * 2016-10-28 2019-06-04 茂英基因科技股份有限公司 辨识转移性肿瘤的原发位置的方法及系统
CN111094594A (zh) * 2017-07-17 2020-05-01 茂英基因科技股份有限公司 产生复数候选探针和鉴定哺乳动物中细胞类型的方法
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
WO2023044118A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) * 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
US20040002071A1 (en) * 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
WO2005108621A1 (en) * 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2007059313A1 (en) * 2005-11-16 2007-05-24 Children's Medical Center Corporation Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1996723A1 (en) * 2006-03-22 2008-12-03 Siemens Medical Solutions Diagnostics GmbH Prediction of breast cancer response to chemotherapy
PT2062049E (pt) * 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
AU2007328427A1 (en) * 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20100233691A1 (en) * 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
US20110160072A1 (en) * 2007-10-23 2011-06-30 Clinical Genomics Pty. Ltd. Method of diagnosing neoplasms
EP2247755B1 (en) * 2008-02-14 2015-01-28 Decode Genetics EHF Susceptibility variants for lung cancer
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
WO2009140556A2 (en) * 2008-05-15 2009-11-19 University Of Southern California Genotype and expression analysis for use in predicting outcome and therapy selection
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.

Similar Documents

Publication Publication Date Title
RU2011102743A (ru) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
Zaha Significance of immunohistochemistry in breast cancer
JP2011528442A5 (enExample)
JP5750152B2 (ja) 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
JP2020126077A (ja) Ｓｔ２心臓バイオマーカのための検査装置および方法
JP2013505429A5 (enExample)
JP2018504609A5 (enExample)
US20170089903A1 (en) Biomarkers for detection of breast cancer in women with dense breasts
Rutledge et al. Sentinel node micrometastasis in breast carcinoma may not be an indication for complete axillary dissection
US20180180617A1 (en) Intergrin alpha v beta 6 for diagnosis/prognosis of colorectal carcinoma
JP2010535014A5 (enExample)
JP2021523379A5 (enExample)
CN106662543A (zh) 肺癌患者中的非侵入性基因突变检测
ES2551713T3 (es) Procedimientos para el diagnóstico o pronóstico de cáncer colorrectal
Li et al. AGR2 diagnostic value in nasopharyngeal carcinoma prognosis
JP2012526543A5 (enExample)
JP2025518766A (ja) 胃癌発病可能性の予測のためのバイオマーカー及びその用途
Tay et al. Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer
CN106383231B (zh) 一种诊断肝癌的标记物组合及其应用
US7951544B1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
KR20240157611A (ko) 전이성 유방암의 항암제 치료 반응성 및 예후 예측용 신규한 바이오마커 및 이의 용도
Innaro et al. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology
CN119630966A (zh) 用于对膀胱癌进行风险分层和管理的方法和系统
KR102136747B1 (ko) 장형 위암의 예후 진단 마커
JP7239139B2 (ja) 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法